Pfizer Commitment to Gaucher Disease
Pfizer–Committed to Discovering New Therapies for Rare Diseases
As one of the world's largest research-based pharmaceutical companies, Pfizer is committed to helping address the unmet medical needs of people with rare diseases. Pfizer partners with advocacy groups, academic organizations, and biopharmaceutical companies to discover, develop, and deliver new treatments and support programs for rare diseases.
In 2009, Pfizer and Protalix Biotherapeutics entered into an agreement to further develop and bring ELELYSO™ (taliglucerase alfa) for injection to the United States. This agreement is just one way each company has demonstrated their commitment to the rare disease community, including Gaucher disease.
Protalix–A Personal Connection to Gaucher Disease
Even though Gaucher disease is a rare disease, it is very familiar to the employees of Protalix, an Israeli-based biotech company. Many have family members and friends who have personal experience with Gaucher disease so the employees truly understand the impact it can have on patients and their families. Out of their passion to improve these patients' lives, ELELYSO was developed as a treatment for Type 1 Gaucher disease.
Introducing the Patient Affairs Liaison
A Pfizer Patient Affairs Liaison is available to help provide a high level of support for patients. Patients and their family members can call with general questions about Pfizer, feedback about service provided by the Gaucher Personal Support program, and assistance with finding additional Gaucher-related resources.
The Patient Affairs Liaison will:
- Monitor patient feedback to help provide a high level of customer service
- Coordinate with and serve as the Pfizer contact for Gaucher advocacy groups
You can contact your Patient Affairs Liaison, Mariah K., RN, at: GaucherPatientAffairs@pfizer.com.